

# Medexus Pharmaceuticals Inc

16:35 02 Dec 2019

## Mackie repeats Buy rating on Medexus Pharmaceuticals on growing product demand

Mackie Research on Monday repeated a Buy rating on Medexus Pharmaceuticals Inc (CVE:KMDP) (OCTMKTS:PDDPF) after it posted second-quarter results showing strong demand for its leading products.

Medexus is focused on the therapeutic areas of auto-immune disease and pediatrics. The leading products are Rasuvo and Metroject, designed to treat rheumatoid arthritis and other auto-immune diseases; and Rupall, an innovative allergy medication.

"Specifically, Metroject unit market demand increased 115%, Rasuvo unit market demand increased 15%, and Rupall unit market demand increased 66% over the same period last year," CEO Ken d'Entremont said in a statement on Monday.

### READ: Medexus Pharmaceuticals posts strong year-over-year increase in 2Q revenue

Those numbers, especially for Rasuvo and Metroject, impressed analysts at Mackie.

"We believe the growth trajectory of Rasuvo and Metroject unit sales should continue going forward as originally expected," wrote analysts Andre Uddin and Yue (Toby) Ma in their note.

The analyst also noted that Medexus has "three pillars of growth" — organic growth of existing drugs, in-licensing and acquisitions of new products and the development of a reformulated rheumatoid arthritis drug that should have a better safety profile.

"We believe MDP is a must-own for investors investing in the Canadian specialty pharma space as the stock is highly undervalued and the company is in a strong position to deliver robust long-term growth. We are maintaining our Buy rating and target price of C\$10.50," the analysts wrote.

Medexus' stock trades around C\$3.90 a share.


Contact the author: [patrick@proactiveinvestors.com](mailto:patrick@proactiveinvestors.com)

Follow him on Twitter @PatrickMGraham

**Price:** 3.75

**Market Cap:** \$53.03 m

### 1 Year Share Price Graph



January 2019 July 2019 January 2020

### Share Information

**Code:** MDP

**Listing:** TSX-V

| 52 week | High | Low  |
|---------|------|------|
|         | 5.08 | 3.34 |

**Sector:** Pharma & Biotech

**Website:** [www.medexusinc.com](http://www.medexusinc.com)

### Company Synopsis:

Medexus is a leading specialty pharmaceutical company with a strong North American commercial platform. The Company's vision is to provide the best healthcare products to healthcare professionals and patients, through our core values of Quality, Innovation, Customer Service and Teamwork. Medexus Pharmaceuticals is focused on the therapeutic areas of auto-immune disease, pediatrics, and specialty oncology.

[action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 [action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

### No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Medexus Pharmaceuticals Inc named herein, including the promotion by the Company of Medexus Pharmaceuticals Inc in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount 

|    |    |        |      |          |         |             |
|----|----|--------|------|----------|---------|-------------|
| up | to | Twenty | Five | Thousand | dollars | (\$25,000). |
|----|----|--------|------|----------|---------|-------------|